Literature DB >> 19906241

Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning.

Anne T Spijker1, Elisabeth F C van Rossum.   

Abstract

Previously, it has been suggested that hypothalamic-pituitary-adrenal (HPA) axis dysregulation and, as a consequence, increased cortisol levels, is not only a state phenomenon, but may also be a trait phenomenon in mood disorders. Cortisol exerts its effects mainly by binding to the glucocorticoid receptor (GR) and, of particular interest in certain brain regions, the mineralocorticoid receptor (MR). Several GR polymorphisms have been shown to be associated with altered sensitivity of the HPA axis. Recently, the GR polymorphisms BclI and ER22/23EK have been associated with unipolar depression in several studies. In addition, the ER22/23EK polymorphism seems to be associated with a decreased risk of dementia in healthy individuals. Also, during a depressive episode, carriers of this ER22/23EK variant demonstrated a tendency toward better cognition, as measured by divided attention tests. In this overview, currently known clinically relevant GR and MR polymorphisms are discussed in relation to mood disorders (both unipolar depression and bipolar disorder) and cognitive function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906241     DOI: 10.1111/j.1749-6632.2009.04985.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  The relationship of serum cortisol levels with depression, cognitive function and sleep disorders in chronic kidney disease and hemodialysis patients.

Authors:  Baris Afsar
Journal:  Psychiatr Q       Date:  2014-12

2.  A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory.

Authors:  Sandra Cornelisse; Marian Joëls; Tom Smeets
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 4.  Conference summary and conclusions. A comprehensive approach to predicting and managing mood effects of glucocorticoids.

Authors:  Esther M Sternberg; Lewis L Judd
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 5.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

6.  Developmental methamphetamine exposure results in short- and long-term alterations in hypothalamic-pituitary-adrenal-axis-associated proteins.

Authors:  Damian G Zuloaga; Jessica A Siegel; Summer F Acevedo; Maayan Agam; Jacob Raber
Journal:  Dev Neurosci       Date:  2013-07-11       Impact factor: 2.984

7.  Epigenetic Modulation of Mood Disorders.

Authors:  T Archer; M Oscar-Berman; K Blum; Ms Gold
Journal:  J Genet Syndr Gene Ther       Date:  2013-02-11

Review 8.  The hypothalamic-pituitary-adrenal axis as a substrate for stress resilience: Interactions with the circadian clock.

Authors:  Scott A Kinlein; Ilia N Karatsoreos
Journal:  Front Neuroendocrinol       Date:  2019-12-19       Impact factor: 8.606

9.  Genetics of cortisol secretion and depressive symptoms: a candidate gene and genome wide association approach.

Authors:  Fleur P Velders; Maris Kuningas; Meena Kumari; Marieke J Dekker; Andre G Uitterlinden; Clemens Kirschbaum; Karin Hek; Albert Hofman; Frank C Verhulst; Mika Kivimaki; Cornelia M Van Duijn; Brian R Walker; Henning Tiemeier
Journal:  Psychoneuroendocrinology       Date:  2011-02-12       Impact factor: 4.905

Review 10.  Cognitive function, dementia and type 2 diabetes mellitus in the elderly.

Authors:  Mark W J Strachan; Rebecca M Reynolds; Riccardo E Marioni; Jacqueline F Price
Journal:  Nat Rev Endocrinol       Date:  2011-02       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.